Want to see JP:4527 full AI Analyst Report?
4527 Stock Chart & Stats
¥3055.00
-¥41.00(-1.62%)
At close: 4:00 PM EDT
¥3055.00
-¥41.00(-1.62%)
Day’s Range― - ―
52-Week Range¥2,218.50 - ¥3,122.00
Previous CloseN/A
Volume1.22M
Average Volume (3M)1.48M
Market Cap
¥707.39B
Enterprise Value¥531.68K
Total Cash (Recent Filing)¥84.77B
Total Debt (Recent Filing)¥58.10B
Price to Earnings (P/E)20.7
Beta0.46
Next Earnings
Nov 12, 2026EPS Estimate
32.14Next Dividend Ex-DateN/A
Dividend Yield1.51%
Share Statistics
EPS (TTM)146.61
Shares Outstanding236,178,310
10 Day Avg. Volume1,269,930
30 Day Avg. Volume1,477,600
Financial Highlights & Ratios
PEG Ratio1.40
Price to Book (P/B)1.80
Price to Sales (P/S)1.58
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,950.00Price Target Upside-3.44% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)158.37
Revenue Forecast (FY)¥370.50B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe near-doubling of revenue over five years indicates durable brand demand, effective retail and pharmacy distribution, and successful expansion across healthcare and personal-care categories.
ProfitabilitySustained profitability and healthy returns on equity show that Rohto converts its branded product portfolio into earnings efficiently, supporting reinvestment in innovation, marketing, and international growth.
Balance Sheet And Cash FlowLow leverage and a growing equity base provide financial resilience, while rising free cash flow supports product development, overseas expansion, and shareholder commitments without excessive balance-sheet strain.
Bears Say
Margin CompressionPersistent margin erosion suggests higher input, labor, promotion, or product-mix costs are absorbing part of the benefit from growth, potentially limiting earnings expansion unless operating efficiency improves.
Higher DebtAlthough leverage remains manageable, the sizable debt increase introduces greater fixed financial obligations and reduces the cushion available for acquisitions, investment, or periods of weaker consumer demand.
Cash Conversion VolatilityUneven conversion of accounting earnings into operating cash may reflect working-capital swings or reinvestment needs, making internally funded growth and debt reduction less predictable over the medium term.
Rohto Pharmaceutical Co News
4527 FAQ
What was Rohto Pharmaceutical Co Ltd’s price range in the past 12 months?
Rohto Pharmaceutical Co Ltd lowest stock price was ¥2218.50 and its highest was ¥3122.00 in the past 12 months.
What is Rohto Pharmaceutical Co Ltd’s market cap?
Rohto Pharmaceutical Co Ltd’s market cap is ¥707.39B.
When is Rohto Pharmaceutical Co Ltd’s upcoming earnings report date?
Rohto Pharmaceutical Co Ltd’s upcoming earnings report date is Nov 12, 2026 which is in 69 days.
How were Rohto Pharmaceutical Co Ltd’s earnings last quarter?
Rohto Pharmaceutical Co Ltd released its earnings results on Aug 06, 2026. The company reported ¥47.14 earnings per share for the quarter, beating the consensus estimate of ¥39.86 by ¥7.28.
Is Rohto Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Rohto Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Rohto Pharmaceutical Co Ltd pay dividends?
Rohto Pharmaceutical Co Ltd pays a Semiannually dividend of ¥25 which represents an annual dividend yield of 1.51%. See more information on Rohto Pharmaceutical Co Ltd dividends here
What is Rohto Pharmaceutical Co Ltd’s EPS estimate?
Rohto Pharmaceutical Co Ltd’s EPS estimate is 32.14.
How many shares outstanding does Rohto Pharmaceutical Co Ltd have?
Rohto Pharmaceutical Co Ltd has 236,178,310 shares outstanding.
What happened to Rohto Pharmaceutical Co Ltd’s price movement after its last earnings report?
Rohto Pharmaceutical Co Ltd reported an EPS of ¥47.14 in its last earnings report, beating expectations of ¥39.86. Following the earnings report the stock price went up 2.472%.
Which hedge fund is a major shareholder of Rohto Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in JP:4527
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Rohto Pharmaceutical Co Ltd
Established in Osaka, Japan, in 1899, Rohto Pharmaceutical Co.,Ltd. is a global entity engaged in the development, manufacturing, and marketing of a diverse array of pharmaceutical goods, beauty products, and nutritional supplements. Their comprehensive product line includes various ophthalmic solutions such as eye drops, contact lens care products, and eye washes. For skincare, they offer facial treatments like cleansers, toners, and creams, in addition to specialized medicated preparations for the skin. The company's offerings also extend to internal medicines, encompassing digestive aids, herbal remedies, and dietary supplements. Furthermore, they supply over-the-counter medications and deliver beauty and health services via dedicated counters. The company rebranded from Yamada Pharmaceutical to Rohto Pharmaceutical Co.,Ltd. in September 1949.
4527 Stock 12 Month Forecast
Average Price Target
¥2,950.00
▼(-3.44% Downside)